ABSTRACT We studied platelets of patients with the genetic disorder pseudohypoparathyroidism (PHP) to test whether the nucleotide-binding proteins mediating stimulation of adenylate cyclase (termed NS) are identical to those mediating inhibition of cyclase (termed Ni). Functional responses to hormones that work through stimulation of adenylate cyclase are blunted in PHP patients. The erythrocytes of many of these patients (PHP-Ia) have previously been shown to have decreased Ns activity whereas those of other PHP patients (PHP-Ib) have normal Ns activity. We find that this decreased Ns activity (measured by the ability to restore adenylate cyclase activity to membranes prepared from S49 cyccells) also occurs in the platelets of PHP-Ia but not of PHP-Ib patients. Platelets from both groups of patients accumulate less cAMP in response to prostacyclin than do platelets from control subjects. In contrast to the decreased Ns function in patients with PHP-Ia, we find that Ni function in platelets is similar in these patients and control subjects in several types of experiments: (i) epinephrine-mediated inhibition ofprostacyclin-stimulated cAMP production in intact platelets; (ii) the affinity of platelet a%-adrenergic receptors for epinephrine, as determined by competition for [3H]yohimbine binding; (iii) the decrease in receptor affinity for epinephrine produced by Na+ and GTP; and (iv) 
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METHODS
Patients. Seven patients with PHP were studied; these were the same patients reported previously (7) . Previous assays demonstrated decreased activity of erythrocyte N, in three of the patients (PHP-Ia) but not in four others (PHP-Ib) (7) . Control platelets were obtained from healthy men (ages 22-45) who had taken no medication for at least 1 wk.
Platelets. Blood was drawn into 60-ml plastic syringes containing 6 ml of 3.8% sodium citrate and centrifuged at 300 X g for 20 min, and the platelet-rich plasma was removed. The packed erythrocytes were mixed with an equal volume of 100 mM NaCl/5 mM EDTA/50 mM Tris-HCl, pH 7.5, and were centrifuged twice. The platelet-rich plasma and the two extracts were combined and centrifuged at 5,000 X g for 10 min and the pellet was washed twice by the same procedure. Determination of cAMP accumulation and some of the radioligand binding assays were carried out with intact platelets suspended in 50 mM Tris-HCl/100 mM NaCV5 mM EDTA, pH 7.5. In other raAbbreviations: PHP, pseudohypoparathyroidism; Ni, nucleotide binding unit coupled to inhibition ofadenylate cyclase; N,, nucleotide binding unit coupled to stimulation ofadenylate cyclase; PGI2, prostaglandin I2 or prostacyclin. 4193 The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. dioligand experiments, the platelets were suspended in 5 mM Tris, pH 7.5/0.5 mM EDTA at 40C and homogenized with a "zero-clearance" motor-driven Teflon-tipped homogenizer (Kontes models K886031 and K885752). The homogenate was centrifuged at 30,000 x g for 10 min and the pellet was washed three times. The final particulate (or "membrane") suspension ("'0.3 mg/ml) was kept ice cold until used.
Ns Assay. The variant S49 cyc-mouse lymphoma cells contain (3 adrenergic receptors and adenylate cyclase but no functional N.. One method to assay Ns is to determine the degree to which adenylate cyclase activity can be restored to membranes prepared from these S49 cyc-cells. We assayed N, activity in the platelets from the PHP patients by using this reconstitution assay as described (9) . The platelet membranes were pelleted, resuspended to a concentration of0.5 mg ofprotein per ml, and then treated with 0.2% Lubrol 12A9 for 60 min at 00C. The suspension was centrifuged at 100,000 X g for 45 min and the supernatant fractions were incubated at 370C for 15 min to inactivate the catalytic subunit of adenylate cyclase. Various amounts (0-5 ,ul) of this soluble platelet extract were then mixed with 15 Ag of membranes prepared from cyc& S49 cells, and cAMP synthesis was assayed after 40 min ofincubation with 100 ,uM guanosine 5-[y-thio]triphosphate. The adenylate cyclase assay conditions were identical to those used previously (9, 10) .
cAMP Assay. Washed platelets were suspended in Hanks' balanced salt solution lacking calcium and magnesium salts but including 5 mM NaHepes/0.5 mM 1-methyl-3-isobutylxanthine, pH 7.6, to a concentration of =0.25 mg/ml. Duplicate or triplicate aliquots of the platelet suspension (0.38 ml), dispensed into 12 x 75 mm polypropylene tubes, were incubated for 30 min at 37°C to allow basal cAMP levels to equilibrate. Drugs were added in a volume of 0.40 ml. Because PGI2 is very unstable in solution at neutral pH, it was prepared at a concentration of 1 mg/ml in alkaline buffer and diluted immediately before use in the incubations with platelets. After 1 min of incubation of platelets with drugs, 0.1 ml of 40% (wt/vol) trichloroacetic acid, containing -15,000 cpm of [3H]cAMP, was added. The mixtures were incubated at room temperature for at least 30 min and then centrifuged at 900 X g for 5 min. The supernatants from the tubes were separately applied to columns containing 1 g of Dowex AG50-X8 resin, and the columns were washed twice with 1.2 ml ofwater to remove the trichloroacetic acid and with 4 ml of distilled water to elute the cAMP. This eluate was Iyophilized to dryness in a Savant-Vac centrifugal Iyophilizer and the Iyophilate was stored at 0°C prior to assay for cAMP.
The contents of each tube were reconstituted in 50 mM NaOAc, pH 4.0/0.2 mM 1-methyl-3-isobutylxanthine, and an aliquot was assayed for cAMP by using a competitive protein binding method (11) . The platelets of two PHP-Ia patients was reported previously (9) . We now confirm this finding with data from several additional patients. The platelets of PHP-Ia patients demonstrated 63% of the N, activity of simultaneously assayed control subjects (P = 0.002). The platelets of PHP-Ib patients, however, had nearly normal Ns levels (84% of control, P > 0.05; Fig. 1 ).
Ns couples hormone receptors to stimulation of adenylate cyclase. We measured PGI2-stimulated cAMP production in intact platelets of patients and control subjects. The shapes of the dose-response curves (Fig. 2) were similar but the maximal cAMP production of the platelets from the PHP-Ia patients (Fig. 3) was only 67 ± 2% that of simultaneously assayed controls (P = 0.001). The platelets of PHP-Ib patients (Fig. 3 ) also had lower maximal PGI2-stimulated cAMP accumulation than controls (80 ± 3% of control, P = 0.04). There was a great deal of variation between assays even for the same subject determined on separate occasions, making it necessary to assay cAMP accumulation in control subjects and PHP patients in parallel. In every experiment, PHP patients generated less cAMP than did the controls; PHP-Ia platelets produced a maximum of407 ± 63 pmol ofcAMP/mg ofprotein, whereas controls produced activity in platelets from three PHP-Ia patients by studying cAMP accumulation and binding to a%-adrenergic receptors. Ni mediates inhibition of platelet adenylate cyclase by several agents, including the adrenergic agonist epinephrine. We measured the inhibition of PGI2-stimulated cAMP production in intact platelets produced by epinephrine (Fig. 4) . The doseresponse curves were identical in patients and control subjects, and maximal concentrations of epinephrine inhibited PGI2-stimulated cAMP production similarly (by 86 ± 9% and 80 3%, respectively) in patients and control subjects. Platelets from each of the PHP patients were compared with simultaneously assayed control platelets as described in Fig. 2. PGI2 was tested at 100 ng/ml (0.3 MM. The platelets of two of the PHP-Ia patients were assayed two or three times on different days with each determination compared with its own control; for these, results are mean ± SEM. cAMP production was significantly less than control for both -PHP-Ia (P =0.001) and PHP-Ib (P = 0.04) platelets. N   FIG. 4 . Inhibition of PGI2-stimulated cAMP production by epinephrine. Platelets from PHP-Ia (o) and PHP-1b (A) patients and control subjects (m) were incubated with various concentrations of (-)epinephrine and PGI2 at 100 ng/ml (0.3 pM) for 1 min. As described in Fig. 2 5 and Table 1 ). We also found that the concentration of GTP required to decrease the ability ofepinephrine to compete for [3H]yohimbine binding was identical in platelets from patients and from controls (Fig. 6 ). The binding of epinephrine to the a2-adrenergic receptors is also altered by Na' (13, 18) , although the molecular mechanism of this effect is obscure. Na' (alone or with GTP) identically decreased the ability of epinephrine to compete for [3H]yohimbine binding to membranes from platelets of controls and PHP-Ia patients ( Fig. 5 and Table 1 ).
DISCUSSION
The guanyl nucleotide regulatory protein mediating hormonal stimulation of adenylate cyclase, N,, has been probed in biochemical, genetic, and functional studies (2, (20) (21) (22) (23) . Several peptides that comprise purified N, have recently been identified (23) . The existence of an inhibitory coupling protein, termed Ni, has been surmised because some hormones act by inhibiting adenylate cyclase in a GTP-dependent manner (1, 24) . No direct assay for Ni exists and its presence can only be assessed indirectly by the characteristics of hormone-mediated Table L attenuation of adenylate cyclase or by the influence of guanine nucleotides on the binding of agonists to receptors. For this reason, comparatively little is known about Ni.
To determine whether one protein embodies both N5 and N1 activities, we studied the platelets of PHPZIa patients. The tis- Data from experiments shown.in Fig. 5 with platelets from either three control subjects or three PHP-Ia patients were simultaneously analyzed by a computer program that uses iterative nonlinear regression to fit data to equations based on the law of mass action (15 (4, 5) ; that the concentrations of Mn2+ required to block Ni-mediated inhibition of adenylate cyclase by epinephrine are much lower than the concentrations required to block N5-mediated stimulation of adenylate cyclase (1, 25) ; that cholera toxin appears to label proteins associated with N5 (26, 27) but does not appear to label solubilized components included in a high molecular weight complex ofa2-receptors, epinephrine, and (presumably) Ni (27) ; and that the maximal extent to which adenylate cyclase can be stimulated through Ns exceeds that to which it can be inhibited through Ni (28 (32) and N-ethylmaleimide (33) sensitivity of prostaglandin El stimulation and epinephrine inhibition of adenylate cyclase, and (iii) differences in sensitivity of prostaglandin El and epinephrine stimulation of GTPase to N-ethylmaleimide (33) .
